MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

37.84 0.83

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.08

Max

37.85

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 51M
Verkäufe	39M 239M
KGV Branchendurchschnitt	11.593 87.826
EPS	1.08
Gewinnspanne	21.242
Angestellte	268
EBITDA	14M 73M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+18.64% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	429M 2.1B
Vorheriger Eröffnungskurs	37.01
Vorheriger Schlusskurs	37.84

Nachrichtenstimmung

By Acuity

34%

66%

106 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Jan. 2026, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. Jan. 2026, 21:39 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. Jan. 2026, 20:54 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- Update

8. Jan. 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks

8. Jan. 2026, 17:05 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. Jan. 2026, 16:43 UTC

Wichtige Markttreiber

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. Jan. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. Jan. 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. Jan. 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. Jan. 2026, 21:53 UTC

Ergebnisse

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. Jan. 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. Jan. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. Jan. 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. Jan. 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. Jan. 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. Jan. 2026, 17:48 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Jan. 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. Jan. 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. Jan. 2026, 15:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Defends Its Hostile Bid for Warner -- Update

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

18.64% Vorteil

12-Monats-Prognose

Durchschnitt 43.6 USD 18.64%

Hoch 55 USD

Tief 32 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

106 / 372 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.